BDR Pharma buys majority stake in oral care biz of Acme Formulation
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓BDR Pharma will acquire a controlling stake in Acme Formulation's oral solid business from shareholders led by PAG.
- ✓The deal values the business at ₹2,370 crore.
- ✓Dharmesh Shah said, "We see this as part of a larger growth roadmap." This move helps BDR expand its product offerings in international markets.
Story at a Glance
- Category
- Indian Markets
- Reported By
- Business Line
- Reading Speed
- 2 Minute(s)
- Market Focus
- India Economy
BDR Pharma will acquire a controlling stake in Acme Formulation's oral solid formulations business and its subsidiaries from its existing shareholders, led by PAG.
The transaction values the business at about ₹2,370 crore ($250 million), said sources close to the deal.
The acquisition aligns with BDR's growth priorities across oncology, critical care and women's healthcare, while creating opportunities to expand its product offerings in international markets.
A key strategic rationale for the acquisition is the addition of complementary capabilities across thyroid products, female sex hormone products and general pharmaceutical products. o3 Capital acted as the exclusive financial advisor to BDR Pharma on the transaction.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Business Line
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.